116.84
-3.82 (-3.17%)
| Previous Close | 120.66 |
| Open | 120.53 |
| Volume | 485,406 |
| Avg. Volume (3M) | 590,871 |
| Market Cap | 3,839,643,648 |
| Price / Sales | 4.88 |
| Price / Book | 24.29 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2026 |
| Profit Margin | -15.90% |
| Operating Margin (TTM) | -19.49% |
| Diluted EPS (TTM) | -3.12 |
| Quarterly Revenue Growth (YOY) | 20.30% |
| Total Debt/Equity (MRQ) | 848.67% |
| Current Ratio (MRQ) | 5.71 |
| Operating Cash Flow (TTM) | 47.53 M |
| Levered Free Cash Flow (TTM) | 26.95 M |
| Return on Assets (TTM) | -4.37% |
| Return on Equity (TTM) | -111.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | iRhythm Holdings, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.30 |
|
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 115.08% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 215.00 (JP Morgan, 84.01%) | Buy |
| Median | 200.00 (71.17%) | |
| Low | 198.00 (Canaccord Genuity, 69.46%) | Buy |
| Average | 204.50 (75.03%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 144.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Mar 2026 | 214.00 (83.16%) | Buy | 119.64 |
| Truist Securities | 23 Feb 2026 | 200.00 (71.17%) | Buy | 141.22 |
| Baird | 20 Feb 2026 | 200.00 (71.17%) | Buy | 150.96 |
| Canaccord Genuity | 20 Feb 2026 | 198.00 (69.46%) | Buy | 150.96 |
| JP Morgan | 20 Feb 2026 | 215.00 (84.01%) | Buy | 150.96 |
| Wells Fargo | 20 Feb 2026 | 200.00 (71.17%) | Buy | 150.96 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LAWRENCE BRIAN LEE | - | 119.18 | -1,014 | -120,849 |
| Aggregate Net Quantity | -1,014 | |||
| Aggregate Net Value ($) | -120,849 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 119.18 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LAWRENCE BRIAN LEE | Officer | 04 May 2026 | Sell (-) | 1,014 | 119.18 | 120,849 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |